Aurion Biotech files for IPO amid legal battle with Alconnews2025-01-27T14:48:51+00:00January 27th, 2025|Endpoints News|
Swarm Oncology launches with T cell therapy technology to treat solid tumorsnews2025-01-27T00:00:05+00:00January 27th, 2025|Endpoints News|
Chinese startup begins first clinical trial using CRISPR to edit cells directly in the bone marrownews2025-01-22T20:02:34+00:00January 22nd, 2025|Endpoints News|
FDA rejects Atara’s cell therapy for rare transplant complication, stock cratersnews2025-01-16T14:27:53+00:00January 16th, 2025|Endpoints News|
Vertex’s fertility support bid is ‘self-serving,’ HHS saysnews2025-01-15T20:21:52+00:00January 15th, 2025|Endpoints News|
Umoja’s $100M Series C will advance its bid for more convenient cell therapiesnews2025-01-14T16:44:53+00:00January 14th, 2025|Endpoints News|
The embryo editing debate is back, revived by Nature articlenews2025-01-12T17:21:58+00:00January 12th, 2025|Endpoints News|
Tune Therapeutics raises $175M Series B for epigenetic editingnews2025-01-12T13:00:38+00:00January 12th, 2025|Endpoints News|
Shoreline cuts staff as its partnership with Gilead’s Kite is now in fluxnews2025-01-09T21:05:21+00:00January 9th, 2025|Endpoints News|
First-ever gene edit of infant boy leads to apparent curenews2025-01-08T20:57:25+00:00January 8th, 2025|Endpoints News|
